Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b open-label study of mezagitamab in primary IgA nephropathy
jRCT2011220009Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of mezagitamab in IgA nephropathy (IgAN) and IgA vasculitis nephritis, sponsored by Takeda. Primary endpoints: Main Study: Treatment-emergent adverse events, LTE Observation Period: Treatment-emergent adverse events and 1 more. Started Nov 2022; status: completed.
02
Drugs
mezagitamab
03
Conditions
IgA nephropathy (IgAN)IgA vasculitis nephritis
Beyond the preview
Go deeper on jRCT2011220009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220009.